Silver Book Fact

Effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset

A study of the effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset found an estimated impact on long-term health outcomes of 564 quality-adjusted life-years saved per 1,000 patients over 30 years.

Fagan, SC, LB Morgenstern, A Petitta, RE Ward, BC Tilley, JR Marler, SR Levine, JP Broderick, TG Kwiatkowski, M Frankel, TG Brott, and MD Walker; for the NINDS rt-PA Stroke Study Group. Cost- Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke. Neurology. 1998; 50(4): 883-890. http://www.neurology.org/content/50/4/883.abstract

Reference

Title
Cost- Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Publication
Neurology
Publication Date
1998
Authors
Fagan, SC, LB Morgenstern, A Petitta, RE Ward, BC Tilley, JR Marler, SR Levine, JP Broderick, TG Kwiatkowski, M Frankel, TG Brott, and MD Walker; for the NINDS rt-PA Stroke Study Group
Volume & Issue
Volume 50, Issue 4
Pages
883-890
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Total of physician office visits for first-listed stroke patients in 2014
    There were a total of 1,950,000 physician office visits in 2014 for patients first-listed for a stroke diagnosis.  
  • The projected economic value of eliminating deaths from heart disease is approximately $48 trillion.  
  • In 1996, fewer than 2 in 3 patients were receiving beta-blocker drugs to prevent a second heart attack. In 2006, more than 97% of heart attack patients received these treatments,…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.